Birincil kaynak kaydı
Karar niteliğindeÖn sonuçlar
Pfizer: LITFULO Faz 3 üst düzey sonuçları nonsegmental vitiligo'da olumlu
Two pivotal Phase 3 trials (TRANQUILLO, TRANQUILLO 2) met co-primary endpoints, showing statistically significant facial and total-body repigmentation versus placebo at Week 52. Pfizer plans to submit global regulatory filings for LITFULO as an oral systemic therapy for adults with nonsegmental vitiligo.
Temel olgular
- Bildirildi
- 30 Tem 2026 10:45
- Olay
- Ön sonuçlar
- Yön
- Olumlu
- Şirket
PFEPfizer- Varlık
- ritlecitinib
- Kaynak
- Şirket basın bülteni
- Güvenilirlik
- Kaynaklı
- F-VASI75
- Hafta 52'de Yüz Vitiligo Alan Skorlama Endeksi'nde ≥75% iyileşme
- T-VASI50
- Hafta 52'de Toplam Vitiligo Alan Skorlama Endeksi'nde ≥50% iyileşme
- TRANQUILLO kayıt
- 607 yetişkin ve ergen
- TRANQUILLO 2 kayıt
- 1.567 yetişkin
Kaynak alıntısı
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo Two pivotal studies of LITFULO™ (ritlecitinib) in nonsegmental vitiligo met their co-primary endpoints, showing significant improvement in facial and total repigmentation versus placebo at Week 52 LITFULO was studied in the largest Phase 3 program to date evaluating an oral systemic therapy for nonsegmental vitiligo and has the potential to be a new treatment option for adults Pfizer Inc. (NYSE: PFE) today announced positive topline results from two Phase 3 trials evaluating the efficacy